PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(04): 360-363
DOI: 10.1055/s-0041-1736680
Drug Review

Selinexor—A Drug Review

Hridya Jayamohanan
1   Department of Medical Oncology; Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
Vaibhav Venniyoor
2   Department of Internal Medicine, Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
Keechilat Pavithran 
1   Department of Medical Oncology; Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Selinexor developed by Karyopharm Therapeutics is the first orally available small-molecule inhibitor of exportin-1 (XPO1). XPO-1 is a protein transporter responsible for the export of macromolecules such as tumor suppressor proteins and oncoprotein mRNAs from the nucleus to the cytoplasm; its inhibition results in blocking of multiple oncogenic pathways. Overexpression of XPO1 is seen in multiple myeloma and various other malignancies and is a poor prognostic marker. Pivotal positive trials have resulted in the approval of selinexor for use in refractory or relapsed diffuse large B cell lymphoma and multiple myeloma. In this review, we briefly cover the drug development, mechanism of action, indications, and toxicities of the drug, and the major pivotal trials.

Keywords

selinexor - XPO-1 - oncoprotein - multiple myeloma


Publikationsverlauf

Artikel online veröffentlicht:
26. November 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Syed YY. Selinexor: first global approval. Drugs 2019; 79 (13) 1485-1494
    CrossrefPubMedGoogle Scholar
  • 2 Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers Basel 2020; 12 (02) 407
    CrossrefPubMedGoogle Scholar
  • 3 Karyopharm Therapeutics. Karyopharm announces FDA approval of XPOVIO™ (selinexor) or the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL). [media release]. 22 June 2020. Available at http://www.karyopharm.com. Accessed Aug 4, 2021
  • 4 Lassman AB, Wen PY, Van Den Bent MJ. et al Efficacy and safety of selinexor in recurrent glioblastoma. J Clin Oncol 2019; 37 (15) 2005 2005 J Clin Oncol 2019; 37(15_suppl): 2005-2005
    CrossrefGoogle Scholar
  • 5 Vogl DT, Dingli D, Cornell RF. et al Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018; 36 (09) 859-866
    CrossrefPubMedGoogle Scholar
  • 6 Gandhi UH, Senapedis W, Baloglu E. et al Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk 2018; 18 (05) 335-345
    CrossrefPubMedGoogle Scholar
  • 7 Chari A, Vogl DT, Gavriatopoulou M. et al Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381 (08) 727-738
    CrossrefPubMedGoogle Scholar
  • 8 Richter J, Madduri D, Richard S, Chari A. Selinexor in relapsed/refractory multiple myeloma. Ther Adv Hematol 2020; 11: 2040620720930629
    CrossrefPubMedGoogle Scholar
  • 9 ClinicalTrials.gov. National Library of Medicine (U.S.). (2020, February). Selinexor Treatment for Refractory Myeloma (STORM) (NCT02336815). https://clinicaltrials.gov/ct2/show/results/NCT02336815. Accessed Aug 4, 2021
  • 10 Kalakonda N, Maerevoet M, Cavallo F. et al Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7 (07) e511-e522
    CrossrefPubMedGoogle Scholar
  • 11 ClinicalTrials.gov. National Library of Medicine (U.S.).(2020, May). Bortezomib, Selinexor and Dexamethasone in Multiple Myeloma patients. (BOSTON) (NCT03110562). https://www. clinicaltrials.gov/ct2/show/NCT03110562. Accessed Aug 4, 2021